COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Social distancing interventions started earlier in the COVID-19 epidemic appear to delay the epidemic curve while interventions started later appear to flatten it, according to a new study published in the Centers for Disease Control and Prevention’s Emerging Infectious Diseases Journal.
The Centers for Medicare & Medicaid Services recently issued new guidance implementing the Medicaid Optional Uninsured COVID-19 Testing (XXIII) Group, established by the Families First Coronavirus Response Act.
CMS Issued New Guidance for States on the Medicaid Optional Uninsured COVID-19 Testing (XXIII) Group
The Centers for Medicare & Medicaid Services (CMS) released guidance on June 2 for states implementing the Medicaid Optional Uninsured COVID-19 Testing (XXIII) Group, established by the Families First Coronavirus Response Act.
The Food and Drug Administration recently created an online compendium page of COVID-19 resources for health care professionals.
The Food and Drug Administration authorized the emergency use of two new products designed to respond to the COVID-19 ventilator shortage.
The Center for Medicare and Medicaid Innovation (CMMI) today announced several COVID-19 related modifications to current and future CMMI alternative payment models (APMs). The adjustments are captured in a summary table and are related to the models’ financial methodologies, quality reporting…
The Centers for Disease Control and Prevention updated its page on COVID-19 transmission to clarify other types of spread beyond person to person, such as by someone touching a surface that has the virus on it and then touching their own face.
The Food and Drug Administration updated guidance to spur wider availability of alcohol-based hand sanitizers during the COVID-19 pandemic.
The Centers for Medicare & Medicaid Services implemented several new infection control actions to combat COVID-19 in nursing homes.
The Food and Drug Administration took steps to encourage and streamline the development of COVID-19 tests whose specimens are collected at home by patients.